Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

News Focus

Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)

Bullboard - Stock Discussion Forum VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and... see more

Add To Watchlist

TSXV:VPT - Post Discussion

VentriPoint Diagnostics Ltd > Medical Device License from Health Canada for VMS+ V4.0.

View:

Post by jopatclo on Aug 21, 2024 8:31pm

Medical Device License from Health Canada for VMS+ V4.0.

Today Ventripoint announced receipt of a Medical Device License from Health Canada for VMS+ V4.0. I’m incredibly appreciative for the progress the Ventripoint team is achieving in evolving our core technology and making its benefits available to the clinical community.

Ultrasound is an important imaging modality for diagnosis and monitoring of cardiac patients. The growing numbers of complex cardiac cases compounds the limited capacity of healthcare providers to deal with increasingly heavy workloads. VMS+ enhances echocardiography with AI to generate key measurements with MRI levels of accuracy.

We are now focusing attention on integrating within clinical workflows and generating insights that enable high quality care with greater efficiency and at lower cost. We are building towards a future where diagnosis and monitoring of cardiac defects and disease is more accessible, more efficient, and less expensive.

https://lnkd.in/gZba922p